At the beginning of July, the star artificial intelligence company Anthropic released Claude Science, an AI product exclusive to scientists and pharmaceutical companies, and announced that it will launch an independent drug research and development project to drop a “bombshell” in the field of AI pharmaceuticals. Immediately after that, domestic AI pharmaceutical company Insilicon Smart announced that it had reached a global strategic cooperation agreement with Japanese pharmaceutical giant Takeda Pharmaceuticals, with a total transaction amount of up to 600 million US dollars. On July 8, Insilicon Smart also announced that Rentosertib, the world's first innovative drug developed by AI, has begun phase III clinical trials. There are more and more signs that AI pharmaceuticals are taking a critical leap forward. They are no longer just a “concept” in the laboratory, but already have actual “delivery value.” In this cutting-edge industry, Chinese companies are making great use of their unique strengths. As a combination of AI and the pharmaceutical field, AI pharmaceuticals are no longer an exclusive racetrack for traditional pharmaceutical companies; they are welcoming global tech giants into the market.

At the beginning of July, the star artificial intelligence company Anthropic released Claude Science, an AI product exclusive to scientists and pharmaceutical companies, and announced that it will launch an independent drug research and development project to drop a “bombshell” in the field of AI pharmaceuticals. Immediately after that, domestic AI pharmaceutical company Insilicon Smart announced that it had reached a global strategic cooperation agreement with Japanese pharmaceutical giant Takeda Pharmaceuticals, with a total transaction amount of up to 600 million US dollars. On July 8, Insilicon Smart also announced that Rentosertib, the world's first innovative drug developed by AI, has begun phase III clinical trials. There are more and more signs that AI pharmaceuticals are taking a critical leap forward. They are no longer just a “concept” in the laboratory, but already have actual “delivery value.” In this cutting-edge industry, Chinese companies are making great use of their unique strengths. As a combination of AI and the pharmaceutical field, AI pharmaceuticals are no longer an exclusive racetrack for traditional pharmaceutical companies; they are welcoming global tech giants into the market.